Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, or the treatment of acromegaly, neuroendocrine tumors, and palliative care in advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA). In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development. Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.
Metrics to compare | DEXTECH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDEXTECHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −32.5x | 11.3x | −0.5x | |
PEG Ratio | 1.78 | −0.23 | 0.00 | |
Price/Book | 8.4x | 5.0x | 2.6x | |
Price / LTM Sales | 59.7x | 10.1x | 3.2x | |
Upside (Analyst Target) | - | 153.4% | 45.2% | |
Fair Value Upside | Unlock | 26.9% | 6.4% | Unlock |